HOME >> BIOLOGY >> NEWS
Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases

Berkeley -- An experimental cancer vaccine using defanged listeria bacteria is showing great promise in animal studies, successfully treating new cancers that have spread into the lungs of mice.

The mouse study, reported in the Sept. 21 issue of the journal Proceedings of the National Academy of Sciences by scientists at Cerus Corp. in Concord, Calif., employs a genetically engineered listeria bacteria based on a strain created by coauthor and University of California, Berkeley, microbiologist Daniel Portnoy. Buoyed by the success of the new cancer vaccine, Cerus scientists now are aiming for human trials.

Cerus ultimately hopes to use the genetically engineered listeria vaccine to target cancers such as pancreatic and ovarian cancer, and possibly leukemia and various solid tumors.

The listeria bacteria are uniquely effective vehicles for a cancer vaccine, Portnoy said, because the bacteria incite a strong "innate" response from the immune system and at the same time sneak cancer antigens into cells to optimally stimulate a potent "acquired" immune response. Together, these two independent arms of the human immune system can deliver a one-two punch to cancer cells. Antigens are like a red flag to a bull -- they draw an attack from cells of the immune system -- but the strength of the immune response depends on how the flag is waved.

"This immune therapy uses bacteria that induce both inflammation and an immune response to specific tumor antigens," which together hit the tumor with generalized antitumor chemicals, such as interferon and tumor necrosis factor, as well as activated T-cells that attack and kill the tumor, Portnoy said. "Listeria is the best bug so far to induce that response. With listeria, innate and acquired immunity work in concert."

Portnoy, a professor of molecular and cell biology and of public health and a member of UC Berkeley's Health Sciences Initiative, identified the genes in listeria that make
'"/>

Contact: Robert Sanders
rls@pa.urel.berkeley.edu
510-643-6998
University of California - Berkeley
29-Sep-2004


Page: 1 2 3 4 5

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Cancer gene MYC emerging as key research target
4. Cancer patient, heal thyself
5. USC researcher named General Motors Cancer Research Scholar
6. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
7. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
8. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
9. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
10. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
11. Dana-Farber launches Center for Applied Cancer Science

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/12/2019)... ... 11, 2019 , ... Neal O’Farrell is one of the first generation of ... executive director of the consumer advocacy non-profit the Identity Theft Council as well as ... the Federal Communications Commission’s Cybersecurity Roundtable and is currently a fellow of the EP3 ...
(Date:4/9/2019)... ... April 09, 2019 , ... The McLeod Center for Cancer Treatment and ... rigorous and voluntary audit conducted by an independent, third-party panel of experts in radiation ... in the United States, McLeod is the only such cancer center in South Carolina. ...
(Date:4/4/2019)... ... April 02, 2019 , ... The live session ... into the connectivity between product risk management (ISO 14971) and the clinical risk ... process. , With increasing global regulation and reimbursement challenges faced by medical device ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... Konica Minolta Precision Medicine, Inc. ... of their inaugural Scientific Advisory Board. , Founded in late 2018, ... individual variability in genes, environment, and lifestyle to more accurately predict, detect, treat ...
(Date:3/18/2019)... ... March 18, 2019 , ... For more than 15 years, USDM ... allow life science companies to easily comply with FDA 21 CFR Part 11 and ... a managed service delivering end-to-end GxP compliance from vendor audit through ongoing validation maintenance, ...
(Date:3/14/2019)... ... March 14, 2019 , ... Open registration for the ... Full Spectrum of Case Management,” continues as CMSA makes plans to host the ... only case management industry conference serving the educational and networking needs of case ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... standard solution for preclinical research organizations. It is a low code, GDPR/21 ... systems and facilities, innovative technology-driven automated data capture and seamless data and ...
Breaking Biology Technology:
Cached News: